Etesian Wealth Advisors Inc. Sells 147 Shares of Abbott Laboratories (NYSE:ABT)

Etesian Wealth Advisors Inc. cut its holdings in shares of Abbott Laboratories (NYSE:ABT) by 1.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,976 shares of the healthcare product maker’s stock after selling 147 shares during the period. Etesian Wealth Advisors Inc.’s holdings in Abbott Laboratories were worth $1,361,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Signature Resources Capital Management LLC purchased a new position in Abbott Laboratories in the fourth quarter worth about $29,000. Transcendent Capital Group LLC bought a new stake in Abbott Laboratories during the fourth quarter valued at approximately $29,000. Richardson Financial Services Inc. purchased a new stake in Abbott Laboratories during the fourth quarter valued at approximately $29,000. True Wealth Design LLC raised its holdings in Abbott Laboratories by 1,677.8% in the 4th quarter. True Wealth Design LLC now owns 320 shares of the healthcare product maker’s stock worth $35,000 after purchasing an additional 302 shares during the period. Finally, Rise Advisors LLC purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at about $37,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock traded down $0.27 during trading on Wednesday, hitting $105.22. 2,076,949 shares of the company’s stock were exchanged, compared to its average volume of 5,775,684. The stock has a market capitalization of $183.04 billion, a price-to-earnings ratio of 32.78, a PEG ratio of 2.54 and a beta of 0.74. The business has a 50-day simple moving average of $104.89 and a 200-day simple moving average of $110.17. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.11 and a current ratio of 1.60. Abbott Laboratories has a 52-week low of $89.67 and a 52-week high of $121.64.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.02. Abbott Laboratories had a net margin of 13.96% and a return on equity of 20.18%. The business had revenue of $9.96 billion for the quarter, compared to analysts’ expectations of $9.88 billion. During the same quarter last year, the company earned $1.03 EPS. The business’s revenue was up 2.2% on a year-over-year basis. On average, research analysts forecast that Abbott Laboratories will post 4.62 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, August 15th. Stockholders of record on Monday, July 15th will be given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.09%. The ex-dividend date is Monday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 68.54%.

Insider Transactions at Abbott Laboratories

In related news, EVP Jr. Robert E. Funck sold 10,097 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $104.57, for a total transaction of $1,055,843.29. Following the completion of the transaction, the executive vice president now owns 211,341 shares in the company, valued at approximately $22,099,928.37. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, EVP Jr. Robert E. Funck sold 10,097 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $104.57, for a total transaction of $1,055,843.29. Following the completion of the sale, the executive vice president now directly owns 211,341 shares in the company, valued at $22,099,928.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Lisa D. Earnhardt sold 22,852 shares of the firm’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $106.25, for a total value of $2,428,025.00. Following the completion of the transaction, the executive vice president now owns 61,462 shares in the company, valued at approximately $6,530,337.50. The disclosure for this sale can be found here. Corporate insiders own 1.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ABT shares. Royal Bank of Canada restated an “outperform” rating and set a $125.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, June 4th. Evercore ISI lifted their target price on Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Barclays lowered their price objective on shares of Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating for the company in a research report on Monday, April 22nd. Raymond James reiterated a “buy” rating and issued a $124.00 target price on shares of Abbott Laboratories in a report on Wednesday, April 24th. Finally, Citigroup cut their price target on shares of Abbott Laboratories from $128.00 to $119.00 and set a “buy” rating on the stock in a report on Wednesday, May 22nd. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $120.64.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.